# Encompass Health Corporation (EHC) Stock Analysis: Exploring a 42% Potential Upside with Strong Buy Ratings

- Link: https://www.directorstalkinterviews.com/encompass-health-corporation-ehc-stock-analysis-exploring-a-42-potential-upside-with-strong-buy-ratings/4121244773
- Published: 2026-03-16T11:23:20+00:00
- Author: Madison Wilson

Encompass Health Corporation (NYSE: EHC), a prominent entity in the healthcare sector
specializing in medical care facilities, is capturing investor attention with its
impressive growth prospects and strong analyst consensus. Headquartered in Birmingham,
Alabama, and operating since 1984, Encompass Health is renowned for providing specialized
inpatient rehabilitative treatment. The company’s extensive network includes operations
across the United States and Puerto Rico, catering primarily to patients recovering
from significant injuries or illnesses.

Investors are particularly drawn to Encompass Health due to its robust market capitalization
of $10.1 billion and its strategic focus on high-demand rehabilitative services.
The company’s current stock price stands at $100.37, showing stability with a negligible
price change, while its 52-week range indicates a volatility between $93.83 and 
$127.18. This presents a unique opportunity for investors, especially when considering
the average analyst target price of $142.73, which suggests a potential upside of
approximately 42.20%.

Despite the lack of a trailing P/E ratio, Encompass Health’s forward P/E is a compelling
15.50, indicating favorable future earnings growth. The company’s EPS of 5.55 further
underlines its earning efficiency. The notable absence of metrics like the PEG ratio
and price-to-book value suggests an opportunity for investors to conduct further
qualitative assessments to understand the underlying growth and value drivers.

With revenue growth clocking in at an impressive 9.90%, Encompass Health is demonstrating
its capacity for consistent expansion, supported by a significant free cash flow
of $296.8 million. The return on equity (ROE) stands at a commendable 24.82%, highlighting
the company’s effective use of shareholders’ equity to generate profit. These financial
metrics underscore Encompass Health’s operational prowess and its potential to deliver
long-term value to investors.

Dividend-oriented investors will appreciate Encompass Health’s dividend yield of
0.76%, coupled with a conservative payout ratio of 12.97%, suggesting ample room
for future dividend growth. This modest yield, while not the highest in the sector,
is bolstered by the company’s strong cash flow, making it a reliable source of passive
income for shareholders.

Analyst sentiment is overwhelmingly positive, with 12 buy ratings and no hold or
sell recommendations. This consensus, combined with a favorable target price range
of $130.00 to $160.00, positions Encompass Health as a strong candidate for growth-
oriented portfolios. The technical indicators present a mixed picture; the stock’s
50-day moving average is slightly below the current price at 103.53, while the 200-
day moving average sits at 114.34, suggesting potential resistance levels. Meanwhile,
the Relative Strength Index (RSI) of 50.70 indicates that the stock is neither overbought
nor oversold, presenting a balanced outlook.

Encompass Health Corporation’s strategic focus on inpatient rehabilitation, coupled
with its solid financial performance, makes it a compelling investment option in
the healthcare sector. As the company continues to leverage its expertise in specialized
rehabilitative care, it remains well-positioned to capitalize on the growing demand
for healthcare services. Investors should consider the combination of strong buy
ratings, significant potential upside, and the company’s operational strengths when
evaluating Encompass Health as a viable addition to their investment portfolios.

Share on:
